Controversy and debate on dengue vaccine series—paper 2: response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs

Inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs”: Dans et al. limited their analysis to the CYD14 (Asian) trial citing that vaccine response may vary between regions and focused only on safety analysis from the 3rd-6th years.The selection of age >=9 years is primarily driven by preplanned analysis of relative risk in the age group >=9 years (i.e., CYD15 wherein >20,000 subjects aged 9-16 years participated) showing a consistent trend in results, which was also observed in the subjects aged >=9 years (post hoc analysis) in CYD14 and CYD57.[...]the authors cannot definitively attribute severe dengue to antibody-dependent enhancement (ADE).